Abstract: Although numerous studies have tried to elucidate the best dialysis modality in end-stage renal disease patients with diabetes, results were inconsistent and varied with the baseline characteristics of patients. Furthermore, none of the previous studies on diabetic dialysis patients accounted for the impact of glycemic control. We explored whether glycemic control had modifying effect on mortality between hemodialysis (HD) and peritoneal dialysis (PD) in incident dialysis patients with diabetes.
INTRODUCTION

D
iabetes mellitus is the leading cause of end-stage renal disease (ESRD) worldwide, 1 and the number of diabetic patients who commence dialysis therapy is constantly increasing. 2, 3 Therefore, nephrologists are confronted with the problem of deciding which dialysis modality should be recommended to these patients in clinical practice. Although dialysis modality is usually determined based on a number of factors, including the patient's clinical condition, socioeconomic status, patient's or physician's preference, and the practice pattern of the institution, several other problems, such as vascular access and peritoneal membrane permeability, should be considered before making a decision for ESRD patients with diabetes mellitus. 2 In addition, patient survival rates in hemodialysis (HD) and peritoneal dialysis (PD) are another issue to consider. To date, numerous previous studies have compared differences in the survival rates between diabetic HD and PD patients, but the results were not consistent. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Heterogeneity of the study population, diverse dialysis duration, and difference in statistical analysis methods might contribute to these discrepant findings among previous studies. 2, 5, 13, 18, 19 Recently, in this point of view, the European Renal Best Practice Diabetes Guideline Development Group proposed that there was a lack of evidence in favor or against a particular dialysis modality as the first choice in ESRD patients with diabetes. 18 The survival advantage of one dialysis modality over another has been found to vary according to the presence of diabetes. 4, 7, 10, 12, 13 However, none of the previous studies on diabetic dialysis patients accounted for the impact of glycemic control, which is known to be closely associated with clinical outcomes in diabetic patients. [20] [21] [22] In this study, we hypothesized that glycemic control might have an impact on better clinical outcomes of one dialysis modality over another in dialysis patients with diabetes. In contrast to most prior studies in which only baseline demographic characteristics and comorbid diseases were adjusted for, 4, 6, 7, 14, 17 various previously demonstrated independent prognostic factors in dialysis patients, such as high-sensitivity C-reactive protein (hs-CRP), residual renal function (RRF), and hemoglobin A 1c (HbA 1c ), were included in the final analysis. In result, we attempted to clarify the impact of glycemic control on the association between dialysis modality and patient survival in incident dialysis patients with diabetes.
METHODS
Ethical Statements
This study was carried out in accordance with the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board at each participating hospital's Clinical Trial Centre. All patients provided their written informed consent before entering the study.
Study Design and Subjects
All diabetic ESRD patients who started HD or PD between August 1, 2008 and September 30, 2013 at 36 centers of the Clinical Research Center for ESRD (CRC for ESRD) in Korea were initially screened for this study. This study was part of a nationwide multicenter joint network prospective cohort study on ESRD patients in Korea designed to improve survival rates and quality of life and to draw up effective treatment guidelines (clinicaltrial.gov NCT00931970). Patients younger than 18 years, with a history of kidney transplantation before dialysis therapy, with underlying active malignancy or acute infection, or who were expected to survive <3 months were excluded before the initial screening. Among 2035 incident dialysis patients, diabetes mellitus was diagnosed in 1163 patients based on diagnostic criteria of the American Diabetes Association (ADA). 23 After excluding 261 patients who failed to maintain dialysis for >3 months, 902 patients were included in the final analysis as the whole cohort. To evaluate the impact of glycemic control, 773 patients were included after excluding 129 patients whose mean HbA 1c levels during the first 6 months were not available ( Figure 1 ).
Data Collection and Follow-up
Demographic, clinical and laboratory data were extracted from the electronic data management system. Demographic and clinical data including age, sex, height, weight, comorbidities, smoking history, and body mass index were collected at the time of study entry. The following laboratory data were measured from fasting blood samples at 3 and 6 months after initiation of dialysis, and every 6 months thereafter: white blood cell, hemoglobin, blood urea nitrogen, creatinine, albumin, glucose, , an intention-to-treat analysis was adopted rather than an as-treated analysis for survival analysis. The dialysis modality at day 90 was considered the initial dialysis modality. Cumulative survival curves were generated by the Kaplan-Meier method, and between-group survival was compared by a log-rank test. The relative hazard ratio (HR) for mortality of PD compared with HD was ascertained using Cox proportional hazard regression models. Violation of the proportional hazard assumption was tested by conducting a visual examination of the log-minus-log plots. To address our hypothesis whether glycemic control had a modifying impact on patient survival rates of one dialysis modality over the other, the interaction between HbA 1c and dialysis modalities were tested. Since HbA 1c levels had an interaction with dialysis modality on survival rates (P for interaction ¼ 0.04), stratified analysis was performed based on the HbA 1c value of 8.0% (<8.0 or !8.0%). The mean value of HbA 1c was used at baseline, 3 months, and 6 months after dialysis initiation. Because HD and PD were not randomly assigned, we performed propensity score (PS) matching for mitigating the confounding effects of different baseline characteristics according to dialysis modalities. PS was calculated by multivariable logistic regression analysis in each HbA 1c group. All covariates were used for PS matching. Patients were matched 1:1 by PS using a nearest-neighbor matching algorithm. PS matching yielded 199 matched pairs in HbA 1c <8.0% and 36 pairs in HbA 1c !8.0%. Supplementary Figure 1 , http:// links.lww.com/MD/A804 shows the distribution of PS in the unmatched and matched groups. To compare baseline characteristics between two dialysis modalities in the matched group, the Wilcoxon signed rank test was used for continuous variables and McNemar test was used for categorical variables. Consecutive survival analysis was performed in each HbA 1c group. Two-sided P values <0.05 were considered statistically significant.
RESULTS
Baseline Characteristics
The baseline data of 902 patients and 773 patients with available HbA 1c are shown in Table 1 . In the whole cohort (n ¼ 902), the mean age was 62.2 AE 11.9 years and 573 patients (63.5%) were male. HD was the initial modality in 637 patients (70.6%) and PD was the initial modality in 265 patients (29.4%). The median value of HbA 1c was 6.4% (IQR ¼ 5.7-7.3). In 773 patients who had HbA 1c measurement, the initial modality was HD in 538 patients (69.6%) and PD in 235 patients (30.4%). There was no significant difference in the proportion of dialysis modality between patients with and without HbA 1c .
Survival Rates According to Dialysis Modality in the Whole Cohort and Patients With Available HbA 1c
During a median follow-up duration of 28 (IQR ¼ 13-41) months, 191 patients among the whole cohort of 902 patients (21.2%) died. The crude death rates were 101.1/1000 patientyears in the HD group and 67.6/1000 patient-years in the PD group. Kaplan-Meier analysis showed that cumulative patient survival was significantly worse in HD patients compared with PD patients (log-rank test, P ¼ 0.009) ( Figure 2A ). The 1-, 2-, and 5-year patient survival rates were 92.0%, 84.0%, and 59.0% for HD patients, whereas they were 97.0%, 90.0%, and 65.0% for PD patients, respectively. In 773 patients whose HbA 1c concentrations were available, Kaplan-Meier curves also revealed that cumulative survival rates were significantly lower in HD compared with PD patients (log-rank test, P ¼ 0.012) ( Figure 2B ). Cox proportional hazard analysis found that PD was associated with a lower risk of death compared with HD in not only the whole cohort but also the available HbA Table 2) .
Impact of Glycemic Control on Survival
Advantage of PD Over HD PS matching resulted in no differences in baseline characteristics between HD and PD in both HbA 1c <8.0% (Table 3) and !8.0% groups (Table 4) . Difference in survival rates between HD and PD varied according to the degree of glycemic control ( Figure 3) . The cumulative survival rates were significantly lower in HD relative to PD in patients with HbA 1c <8.0% (log-rank test, P ¼ 0.021) ( Figure 3A) . However, there was no significant difference in the cumulative survival rates between HD and PD in patients with HbA 1c !8.0% (log-rank test, P ¼ 0.770) ( Figure 3B ). Furthermore, the survival advantage of PD over HD remained consistent in the good glycemic control group even after PS was adjusted in the multivariate model (HbA 1c <8.0%, HR ¼ 0.59, 95% CI ¼ 0.37-0.94, P ¼ 0.03) ( Table 2 ). However, patient survival rates were comparable between 2 dialysis modalities in the poor glycemic control group in PS-adjusted model (HbA 1c !8.0%, HR ¼ 1.21, 95% CI ¼ 0.46-2.76, P ¼ 0.80) as well as in the crude model (Table 2) .
DISCUSSION
Innumerable studies have demonstrated the survival advantage of one dialysis modality over another in diabetic dialysis patients, but the results have been conflicting. In this study, we demonstrate that PD was significantly associated with decreased risk of all-cause mortality compared with HD in Korean incident dialysis patients with diabetes. Moreover, we found that better patient survival in PD was associated with the degree of glycemic control. PD patients had a survival advantage in the good glycemic control group, but not in the poor glycemic control group.
Even though the choice of dialysis modality is a critical issue, it remains an unsettled question in diabetic dialysis patients. Among a number of factors, patient survival is one important concern to consider before determining the dialysis modality. Several previous studies showed that PD patients had a lower risk of death in the first 1 to 2 years after starting dialysis therapy, 2, 4, 6, 9, 15, 16, 19, 24 which was attributed to preserved RRF in these patients. 11, 25 However, this issue was not fully evaluated because of lack of RRF data in previous studies. 4, 6, 16, 24 In 2016 It is noteworthy that the survival advantage of PD was altered by the degree of glycemic control in diabetic patients starting dialysis therapy. The survival advantage of one dialysis modality over the other varied according to the presence of diabetes. 4, 7, 10, 12, 13 However, so far, no study has explored the impact of glycemic control, which is closely related with clinical outcomes in diabetic patients, [20] [21] [22] on the difference in patient survival between the two dialysis modalities in diabetic dialysis patients. In our study, the better survival of PD patients was observed only in patients with HbA 1c <8.0%, suggesting that the survival benefit of PD was robust in the good glycemic control group. The mechanism by which glycemic control exerts an impact on the mortality of PD relative to HD in diabetic ESRD patients can somewhat be explained by peritoneal damage from hyperglycemia and adherence to treatment. Since PD patients are exposed to a large amount of glucose absorbed from the dialysate, 28 continuous exposure to dialysate might worsen glycemic control and induce peritoneal damage in diabetic patients. Indeed, high peritoneal membrane transport characteristic along with increased protein permeability is more commonly accompanied in diabetic PD patients than nondiabetic PD patients. 29 Although an objective assessment of peritoneal damage according to the degree of glycemic control was not performed, we inferred that the detrimental effect of poor glycemic control may accelerate peritoneal damage and late diabetic complications. This, in turn, lessened the survival benefit of PD in patients with HbA 1c !8.0%. Meanwhile, since PD is a home-based modality, a patient's adherence to treatment and their ability to follow instructions are crucial to maintaining therapy. Adherence to therapy was revealed to be associated with the risk of hospitalization and mortality in dialysis patients; 29 in other words, compliant patients had a lower mortality risk. Moreover, a recent study showed that patients starting PD had increased risks of hospitalization and peritonitis, especially in the early period. 30 These findings suggest that adaptation of self-care education is important to reduce mortality risk. 30 Taken together, we suggest that patients in the good glycemic control groups were more compliant, and thus were able to achieve self-care, which may partly contribute to the survival advantage of PD.
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The present study has several limitations. First, even though the PS matching method was used to overcome limitations of nonrandom allocation to dialysis modality, residual confounding effect cannot be totally excluded. It was difficult to examine whether the indication bias of dialysis modality selection exerted any influence on clinical outcomes. However, to date, most studies included only demographics and comorbidities. 4, 6, 7, 14, 17 In contrast, various dialysis-related prognostic factors, including biochemical variables such as hemoglobin, albumin, calcium, phosphorous, and hs-CRP, as well as RRF were used in this study for PS matching to mitigate confounding effect. Second, as HbA 1c values at baseline, 3 months, and 6 months after dialysis initiation were not available in 129 patients, these patients were excluded from the final analysis of PS matching. But there were no significant differences between patients with and without mean HbA 1c levels except the use of erythropoiesis-stimulating agent (ESA). Third, shortened erythrocyte survival and ESA use can discredit HbA 1c as a marker of glycemic control in dialysis patients. To overcome this limitation, hemoglobin concentrations and ESA use were included in PS calculation and it was revealed that there were no significant differences in hemoglobin levels and ESA use between HD and PD after PS matching. Recent evidence indicated that HbA 1c had modest-to-strong correlations with serum glucose, glycated albumin, and serum fructosamine, and these correlations were similar between HD and PD patients. 31 Glycated albumin and fructosamine have been known to be impervious to anemia than HbA 1c , 31 but unfortunately, these surrogates were not available in our cohort. Fourth, the HbA 1c cutoff value of 8.0% used to stratify patients into good and poor glycemic control groups was relatively arbitrary. However, as our subjects were incident dialysis patients and the mean value of HbA 1c at dialysis initiation and during the first 6 months was used, HbA 1c <8.0% was defined as the good glycemic control group according to the ADA guideline for patients with advanced micro or macrovascular complications (stage 3 or worse chronic kidney disease). 32 Fifth, as this study included only Korean incident dialysis patients, results may not be generalized to other populations. Primary outcome in the present study was relatively small compared with those in Western   FIGURE 3 . Kaplan-Meier analysis of all-cause mortality according to dialysis modality in the (A) PS-matched good glycemic control group (HbA 1c <8.0%) and (B) PS-matched poor glycemic control group (HbA 1c !8.0%). Cumulative survival rates were significantly lower in patients on HD compared with PD in good glycemic control group (n ¼ 398, log-rank test, P ¼ 0.021). However, there was no significant difference in survival rates between HD an PD in poor glycemic control group (n ¼ 72, log-rank test, P ¼ 0.770). HbA 1c ¼ hemoglobin A 1c , HD ¼ hemodialysis, PD ¼ peritoneal dialysis, PS ¼ propensity score.
ESRD patients. We surmised that the difference may be attributed to disparate ethnicities, as the mortality rates of our patients were comparable with those of Japanese patients. 33 Lastly, the follow-up duration was relatively short. Notwithstanding these limitations, the present study has distinct strengths. The heterogeneity of the study population has been indicated as a possible reason for discrepant findings among previous studies. According to a recent systematic review of 25 eligible studies by the European Renal Best Practice Diabetes Guideline Development Group, no study included only diabetic patients 18 ; the proportion of diabetic patients ranged from 9% 12 to 61%. 16 On the contrary, we included only incident dialysis patients with diabetes to focus the impact of glycemic control in these patients and to preserve sufficient statistical power. Finally, the present study enrolled nationally distributed subjects from private clinics to tertiary hospitals between 2008 and 2013, suggesting that the results of this study on our nationwide contemporary cohort could be more helpful to provide evidence for deciding optimal dialysis modality for Korean diabetic dialysis patients in the present era.
In conclusion, the overall patient survival of PD was significantly higher compared with that of HD in incident dialysis patients with diabetes. In addition, better patient survival with PD was influenced by the degree of glycemic control. Survival advantage of PD patients was consistent only in the good glycemic control group. These findings suggest that glycemic control may partly contribute to better survival of PD in Korean incident dialysis patients with diabetes. Nevertheless, further well-designed randomized controlled studies are required to delineate the causal relationship between glycemic control and dialysis modality-related mortality in these patients.
